Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC

October 7th 2024

Isabel Preeshagul, DO, MBS, discusses ongoing efforts to expand treatment options for patients with extensive- or limited-stage small cell lung cancer.

Health Canada Expands Indication for Illuccix Diagnostic Kit for PSMA-Targeted Radioligand Therapy in mCRPC

October 7th 2024

Illuccix has been approved in Canada for the selection of patients with mCRPC eligible for treatment with PSMA1-targeted radionuclide therapy.

ELVN-001 Appears Safe and Effective in Relapsed/Refractory CML

October 7th 2024

ELVN-001 generated prolonged signals of clinical activity with a tolerable safety profile in patients with TKI-relapsed, -refractory, or -intolerant CML.

Dr Besse on Mechanisms of Acquired Resistance in EGFR+ Advanced NSCLC

October 4th 2024

Benjamin Besse, MD, PhD, discusses mechanisms of resistance to amivantamab plus lazertinib vs osimertinib in patients with EGFR-mutant, advanced NSCLC.

Patient-Centered Discussions Will Be Critical to Navigate Treatment Selection in EGFR+ NSCLC

October 4th 2024

Isabel Preeshagul, DO, MBS, discusses considerations for treatment selection in the first and second line for patients with EGFR-mutated NSCLC.

Real-World Analysis Shows High, Durable Transfusion Independence Rates With Luspatercept in Lower-Risk MDS

October 3rd 2024

Luspatercept generated high rates of durable transfusion independence for patients with lower-risk myelodysplastic syndrome in a real-world analysis.

Dr Awad on the FDA Approval of Perioperative Nivolumab for Resectable NSCLC

October 3rd 2024

Mark Awad, MD, PhD, discusses the significance of the FDA approval of perioperative nivolumab for patients with resectable NSCLC.

First-Line Versamune HPV Vaccine Bolsters Responses With SOC Pembrolizumab in HPV16+ Recurrent HNSCC

October 3rd 2024

Jared Weiss, MD, discusses survival benefits seen with the therapeutic cancer vaccine Versamune HPV plus first-line pembrolizumab in HPV16-positive HNSCC.

BPd Maintains QOL vs PVd, Supporting Its Use as a New SOC in R/R Myeloma

October 2nd 2024

No significant differences in patient-reported outcomes were observed with BPd vs PVd among patients with relapsed/refractory multiple myeloma.

De-Escalated Neoadjuvant Treatment Does Not Compromise Survival Outcomes in HR+/HER2+ Early Breast Cancer

October 2nd 2024

Oleg Gluz, MD, highlights the feasibility of de-escalated neoadjuvant therapy plus trastuzumab and pertuzumab in patients with HR+/HER2+ breast cancer.

Allogeneic T-Cell Therapy Produces Efficacy at 10 Months in Stage IV Metastatic NSCLC

October 1st 2024

Treatment with Deltacel was safe and showed antitumor activity at 10 months in a patient with stage IV metastatic non–small cell lung cancer.

FDA Grants Priority Review to T-DXd in HR+, HER2-Low/-Ultralow Breast Cancer

October 1st 2024

The sBLA for trastuzumab deruxtecan in hormone receptor–positive, HER2-low or -ultralow breast cancer has been accepted for priority review by the FDA.

Sonrotoclax/Dexamethasone Combo Is Tolerable, Generates Deep Responses in t(11:14)+ R/R Myeloma

September 30th 2024

Sonrotoclax plus dexamethasone was well tolerated and produced early, durable responses in patients with myeloma harboring t(11:14).

Prostate Cancer Awareness Efforts Target Patient Education, Treatment Access, and Survivorship Care

September 30th 2024

Bertram Yuh, MD, discusses the value of genetic testing, long-term disease management, and raising awareness during Prostate Cancer Awareness Month.

P-BCMA-ALLO1 May Be Safe, Rapid, and Active Allogeneic CAR T-Cell Therapy in Pretreated R/R Myeloma

September 30th 2024

Treatment with P-BCMA-ALLO1 demonstrated clinical activity and a manageable safety profile in heavily pretreated, relapsed/refractory multiple myeloma.

Mirvetuximab Soravtansine Gains Traction in Heavily Pretreated FRα+ Platinum-Sensitive Ovarian Cancer

September 29th 2024

Angeles Secord, MD, MHSc, discusses data with mirvetuximab soravtansine in heavily pretreated FRα-positive recurrent, platinum-sensitive ovarian cancer.

Dr Koff on Frontine and Maintenance Treatment Decision-Making in MCL

September 27th 2024

Jean L. Koff, MD, MS, discusses factors that influence treatment decision-making for patients with MCL in the frontline and maintenance settings.

Dr Battiwalla on the Expanding Use of Bispecific Antibodies in NHL

September 27th 2024

Minoo Battiwalla, MD, MS, discusses the variety of bispecific antibodies evaluated for patients with NHL, including DLBCL.

Zelenectide Pevedotin Shows Early Promise as Less Toxic Alternative to Standard Regimens in Bladder Cancer

September 27th 2024

Terence Friedlander, MD, spotlights emerging agents of interest in advanced bladder cancer, including the Nectin-4–targeted therapy zelenectide pevedotin.

Frontline SHR-1701 Plus CAPOX Delivers Superior OS vs CAPOX Alone in Gastric/GEJ Cancer

September 26th 2024

The addition of SHR-1701 to the HER2-negative gastric/GEJ cancer treatment paradigm may enhance the efficacy of current treatments for this population.